SEC Form 4 · accession 0001610717-26-000409
Ascendis Pharma A/S · ASND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mads Bodenhoff
Officer — SVP & PAO
Period of report
Sep 8, 2026
Accepted (ET)
Sep 9, 2026 · 5:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001612042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 8, 2026 | M | 3,000 | $110.00 | A | 3,000 | D | |
| Ordinary Shares | Sep 8, 2026 | S | 3,000 | $270.19 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF1 | $110.00 | Sep 8, 2026 | M | 3,000 | D | — | Oct 11, 2032 | Ordinary Shares | 3,000 | 687 | D |
Explanation of responses
- F1The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.